Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: I-START Clear all
Active, not recruiting Not applicable Interventional

Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers

NCT04870788
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Mindfulness Relaxation, Quality-of-Life Assessment, Questionnaire Administration, Group II (mindfulness waitlist)
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 2, 2026, 2:23 AM EST
Not listed Phase 2 Interventional

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

NCT03561259
View directory record Official record
Conditions
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Interventions
131I-MIBG, 131-MIBG + Vorinostat
Drug
Lead sponsor
Jubilant DraxImage Inc.
Industry
Eligibility
1 Year and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
21
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Nov 2, 2026, 2:23 AM EST
Terminated Phase 1 Interventional

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

NCT00516542
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, DHEA, pharmacological study
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1 Interventional

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

NCT04201873
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
Biological · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1 Interventional

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT02311920
View directory record Official record
Conditions
Gliosarcoma, Supratentorial Glioblastoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Temozolomide
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1 Interventional

Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

NCT01554969
View directory record Official record
Conditions
Rectal Cancer
Interventions
capecitabine + ganetespib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1 Interventional

Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery

NCT00448643
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Vaginal Brachytherapy, Cisplatin, Whole Abdominal Radiation [WAR] Therapy
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Nov 2, 2026, 2:23 AM EST
Terminated Phase 1 Interventional Results available

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00589550
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Thomas Olencki
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 2, 2026, 2:23 AM EST
Recruiting Phase 1 Interventional

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

NCT06566443
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Honokiol
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

NCT00575068
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
IDEC-114
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
4
States / cities
Tucson, Arizona • Rochester, Minnesota • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

ENGAGED: E-Networks Guiding Adherence to Goals for Exercise and Diet

NCT01051713
View directory record Official record
Conditions
Obesity
Interventions
Technology Supported, Standard
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Nov 2, 2026, 2:23 AM EST
Completed No phase listed Observational

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01987726
View directory record Official record
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 2, 2026, 2:23 AM EST
Terminated Phase 1Phase 2 Interventional

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 3 Interventional Results available

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide
Radiation · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

NCT00012012
View directory record Official record
Conditions
Cervical Cancer, Radiation Toxicity
Interventions
Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
17
States / cities
Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 3 Interventional Results available

The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

NCT00726375
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Etanercept (Enbrel)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Nov 2, 2026, 2:23 AM EST
Enrolling by invitation Early Phase 1 Interventional

Cyclosporine Vs Steroids in DRESS

NCT04988256
View directory record Official record
Conditions
DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions
Cyclosporine, Methylprednisolone and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1 Interventional

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

NCT03509012
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
Interventions
Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Tucson, Arizona • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Nov 2, 2026, 2:23 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Flexibility, Alcohol Misuse, and Excitation

NCT06634771
View directory record Official record
Conditions
Behavioral Flexibility, Healthy Volunteers, High Risk Alcohol Use
Interventions
10 Hz transcranial alternating current stimulation (tACS), sham transcranial alternating current stimulation (tACS)
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 2, 2026, 2:23 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals

NCT07650409
View directory record Official record
Conditions
Colorectal Carcinoma, Obesity-Related Malignant Neoplasm
Interventions
Biospecimen Collection, Dietary Intervention, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 2, 2026, 2:23 AM EST
Completed Phase 1 Interventional

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

NCT01662804
View directory record Official record
Conditions
Neuroblastoma
Interventions
3F8 Monoclonal Antibody Combined with Interleukin-2
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Months and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 2, 2026, 2:23 AM EST
Terminated Not applicable Interventional

Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes

NCT04271930
View directory record Official record
Conditions
Sleep, Multiple Myeloma
Interventions
Mindfulness Awareness Practices for Insomnia, Sleep Health Information
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 2, 2026, 2:23 AM EST
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

NCT01254136
View directory record Official record
Conditions
Breast Cancer
Interventions
INCB007839 300mg BID, Trastuzumab, Vinorelbine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Fayetteville, Arkansas • Duarte, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Nov 2, 2026, 2:23 AM EST